Genmab offers $97 per share to acquire Merus in cash.

Genmab is commencing a cash tender offer to purchase all outstanding common shares of Merus for $97.00 per share in cash, less applicable withholding taxes and without interest. The offer is being made pursuant to a previously announced transaction agreement and is subject to the terms outlined in a tender offer statement filed with the SEC. Merus' board of directors recommends accepting the offer.

Genmab has initiated a cash tender offer to acquire all outstanding common shares of Merus for $97.00 per share. This offer is subject to applicable withholding taxes and is being made pursuant to a previously announced transaction agreement. The tender offer is outlined in a statement filed with the U.S. Securities and Exchange Commission (SEC) Stock Market News 2025-10-18^[1].

The board of directors of Merus has recommended that shareholders accept the offer. This strategic move comes as Genmab continues to expand its portfolio and strengthen its position in the biopharmaceutical sector. The acquisition of Merus could bring significant synergies, particularly in the development and commercialization of new drug candidates.

Genmab's recent acquisition of Profound Bio, which included the drug candidate Rina-S, has already shown promising results in the treatment of uterine cancer Genmab encouraged by updated data on cancer drug^[2]. The company is optimistic about the potential of Rina-S and other drug candidates in the pipeline, which could drive future growth and revenue.

The tender offer is a significant event for both companies and their shareholders. Investors should closely monitor the progress of this transaction and the potential impact on both companies' financial performance. The offer is expected to be completed in the coming months, pending regulatory approvals and shareholder acceptance.